Outcome measures for clinical trials in Parkinson’s disease: achievements and shortcomings

REFERENCES

• Fahn S, Elton RL. Unified Parkinson's disease rating scale. In: Recent Developments in Parkinson's disease. Fahn S, Marsden CD, Calne DB, Goldstein M (Eds). MacMillan Healthcare, NJ, USA, 153–163 (1987).
   Google Scholar
• Ramaker C, Marinus J, Stiggelbout AM, Van Hilten BJ. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mow Disord. 17, 867–876 (2002).
   Google Scholar
• Movement Disorder Society Task Force on Rating Scales for Parkinson's D. The Unified Parkinson's disease Rating Scale (UPDRS): status and recommendations. Mow Disord. 18,738–750 (2003).
   PubMed Web of Science ®Google Scholar
• Bennett DA, Shannon KM, Beckett LA, Goetz CG, Wilson RS. Metric properties of nurses' ratings of parkinsonian signs with a modified Unified Parkinson's disease Rating Scale. Neurology 49,1580–1587 (1997).
   Google Scholar
• Duvoisin RC. The evaluation of extrapyramidal disease. In: Monoamines Noyaux Cris Centraux et Syndrome de Parkinson. Ajuriaguerra J, Gauthier G (Eds). Georg & Cie, Geneva, Switzerland, 313–325 (1971).
   Google Scholar
• Webster DD. Clinical analysis of the disability in Parkinson's disease. Mod. Treatment 5,257–282 (1968).
   PubMedGoogle Scholar
• Mitchell SL, Harper DW, Lau A, Bhalla R. Patterns of outcome measurement in Parkinson's disease clinical trials. Neuroepidemiology19,100–108 (2000).
   PubMed Web of Science ®Google Scholar
• Aaronson NK. Quantitative issues in health-related quality of life assessment. Health Pol. 10,217–230 (1988).
   PubMed Web of Science ®Google Scholar
• Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neural. 245, S10 —S14 (1998).
   Google Scholar
• de Boer AG, Wijker W, Speelman JD, de Haes JC. Quality of life in patients with Parkinson's disease: development of a questionnaire. J. Neural. Neurosurg. Psychiatry 61,70-74 (1996). itCalne SM, Mak E, Hall J et al. Validating a quality-of-life scale in caregivers of patients with Parkinson's disease: Parkinson's Impact Scale (PIMS). Advances Neural. 91, 115–122 (2003).
   Google Scholar
• Welsh M, McDermott MP, Holloway RG et aL Development and testing of the Parkinson's disease quality of life scale. Mov. Disord. 18,637–645 (2003).
   PubMed Web of Science ®Google Scholar
• Marinus J, Ramaker C, van Hilten JJ, Stiggelbout AM. Health-related quality of life in Parkinson's disease: a systematic review of disease specific instruments. J NeuroL Neurosurg. Psychiatry 72,241–248 (2002).
   PubMed Web of Science ®Google Scholar
• de Bruin AF, de Witte LP, Stevens F, Diederiks JE Sickness Impact Profile: the state of the art of a generic functional status measure. Soc. Sci. Med. 35,1003–1014 (1992).
   PubMed Web of Science ®Google Scholar
• McHarney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med. Care 31,247–263 (1993).
   Google Scholar
• Hunt SM, McEwen J, McKenna SE Measuring health status: a new tool for clinicians and epidemiologists. J. R. Coll. Gem Prac. 35,185–188 (1985).
   PubMedGoogle Scholar
• EuroQ01 G. EuroQ01: a new facility for the measurement of health related quality of life. Health PoL 12,199–208 (1990).
   Google Scholar
• Kaplan RM, Bush JVV, Berry CC. Health status: types of validity and the index of well-being. Health Serv. Res. 11,478-507 (1976).
   Google Scholar
• Kaplan RM, Anderson JE A general health policy model: update and applications. Health Serv. Res. 23, 203–235 (1988).
   PubMed Web of Science ®Google Scholar
• Feeny D, Furlong W, Boyle M, Torrance GW Multi-attribute health status classification systems. Health Utilities Index. PharmacoEconomics 7,490–502 (1995).
   PubMed Web of Science ®Google Scholar
• Brefel-Courbon C, Desboeuf K, Thalamas C et al. Clinical and economic analysis of spa therapy in Parkinson's disease. Mov Disord. 18,578–584 (2003).
   PubMed Web of Science ®Google Scholar
• Hauser RA, Molho E, Shale H, Pedder S, Dorflinger EE. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients. Tolcapone De novo Study Group. Mov. Disord. 13,643–647 (1998).
   Google Scholar
• The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet353, 2041–2042 (1999).
   PubMed Web of Science ®Google Scholar
• Hutton JT, Metman LV, Chase TN et al. Transdermal dopaminergic D(2) receptor agonist therapy in Parkinson's disease with N-0923 TDS: a double-blind, placebo-controlled study. Mov. Disord. 16,459-463 (2001).
   Google Scholar
• Suchowersky O, Bailey P, Pourcher E, Bulger L, Facciponte G. Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD. Clin. NeuropharmacoL 24,214–220 (2001).
   Google Scholar
• Brunt ER, Brooks DJ, Korczyn AD, Montastruc JL, Stocchi F, The 043 Study G. A 6-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. J Neural Trans. 109,489-502 (2002).
   Google Scholar
• Freed CR, Greene PE, Breeze RE et aL Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N EngL J. Med. 344,710–719 (2001).
   PubMed Web of Science ®Google Scholar
• Clarke CE, Cooper JA, Holdich TA, Group TS. A randomized, double-blind, placebo-controlled, ascending-dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson's disease with response fluctuations. Clin. NeuropharmacoL 24, 133–138 (2001).
   PubMed Web of Science ®Google Scholar
• Carr JA, Honey CR, Sinden M, Phillips AG, Martzke JS. A waitlist control-group study of cognitive, mood, and quality of life outcome after posteroventral pallidotomy in Parkinson's disease. J. Neurosurgery 99, 78–88 (2003).
   Google Scholar
• Fenelon G, Gimenez-Roldan S, MontastrucTh et al Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study. J. Neural 7ians. 110,239-251 (2003).
   Google Scholar
• Wade DT, Gage H, Owen C, Trend P, Grossmith C, Kaye J. Multidisciplinary rehabilitation for people with Parkinson's disease: a randomised controlled study. J. NeuroL Neurosurg. Psychiatry 74,158–162 (2003).
   PubMed Web of Science ®Google Scholar
• Adler CH, Singer C, O'Brien C et aL Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson's disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. Arch. NeuroL 55,1089–1095 (1998).
   PubMedGoogle Scholar
• Baas H, Beiske AG, Ghika J et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the wearing off phenomenon and levodopa requirements in fluctuating parkinsonian patients. Neurology 50, S46—S53 (1998).
   Google Scholar
• Waters CH, Kurth M, Bailey P et aL Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Study Group. Neurology 50, S39—S45 (1998).
   Google Scholar
• Koller W, Lees A, Doder M, Hely M, Tolcapone/Pergolide Study G. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations. Mov. Disord. 16,858–866 (2001).
   Google Scholar
• Jarman B, Hurwitz B, Cook A, Bajekal M, Lee A. Effects of community based nurses specialising in Parkinson's disease on health outcome and costs: randomised controlled trial. Br. Med. J. 324,1072-1075 (2002).
   Google Scholar
• Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopailevodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology53, 1012–1019 (1999).
   Google Scholar
• de Bie RM, de Haan RJ, Nijssen PC et aL Unilateral pallidotomy in Parkinson's disease: a randomised, single-blind, multicentre trial. Lancet 354,1665–1669 (1999).
   PubMed Web of Science ®Google Scholar
• Pacchetti C, Mancini F, Aglieri R, Fundaro C, Martignoni E, Nappi G. Active music therapy in Parkinson's disease: an integrative method for motor and emotional rehabilitation. Psycho. Med. 62, 386–393 (2000).
   Google Scholar
• Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Clin. NeuropharmacoL 23,34–44 (2000).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled trial of rasagiline in early Parkinson's disease: the TEMPO Study. Arch. NeuroL 59, 1937–1943 (2002).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Pramipexole versus levodopa as initial treatment for Parkinson's disease: a randomized controlled trial. JAMA 284,1931–1938 (2000).
   PubMed Web of Science ®Google Scholar
• Scott DL, Garrood T. Quality of life measures: use and abuse. Best Prac. Res. Clin. RheumatoL 14,663–687 (2000).
   PubMed Web of Science ®Google Scholar
• Marras C, Lang AE. Measuring motor complications in clinical trials for early Parkinson's disease. J. NeuroL Neurosurg. Psychiatry74,143–146 (2003).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann. NeuroL 39,37–45 (1996).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson's disease. A randomized dose-ranging study. JAMA 278,125–130 (1997).
   Google Scholar
• Rascal O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A 5-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl. J Med. 342, 1484–1491 (2000).
   Google Scholar
• Cedarbaum JM, Gandy SE, McDowell FH. Early initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology 41,622–629 (1991).
   Google Scholar
• Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopailevodopa in PD. A 5-year randomized multicenter study. Neurology 53,1012–1019 (1999).
   Google Scholar
• Ahlskog JE, Muenter M. The frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16, 448–458 (2001).
   PubMed Web of Science ®Google Scholar
• Rascal O, De Deyn PP, Watts RL, Korczyn A, Lang AE. Reduced dyskinesias with ropinirole in a naturalistic 8.5 year follow-up of patients with early parkinson's disease who had initially received ropinirole or L-dopa. Mov. Disord. 19, S253 (2004).
   Google Scholar
• Parkinson Study Group. Pramipexole versus levodopa as initial treatment for Parkinson's disease: a 4-year randomized controlled trial. Arch. Neural. 61,1044-1053 (2004).
   Google Scholar
• Comparisons of therapeutic effects of levodopa, levodopa, and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. Parkinson's disease Research Group in the United Kingdom. Br. Med. J 307, 469–472 (1993).
   PubMedGoogle Scholar
• Melamed E, Olanow CW, Nutt JG, Lang AE. Dyskinesias assessment workshop: reports from the working groups. Mov. Disord. 14,69–73 (1999).
   PubMed Web of Science ®Google Scholar
• Shults CW, Oakes D, Kieburtz K et al. Effects of coenzyme Q10 in early Parkinson's disease: evidence of slowing of the functional decline. Arch. Neurol. 59, 1541–1550 (2002).
   Google Scholar
• Larsen JP, Boas J, Erdal JE. Does selegiline modify the progression of early Parkinson's disease? Results from a 5-year study. The Norwegian-Danish Study Group. Eur. Neural. 6,539-547 (1999).
   Google Scholar
• Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson's disease. Arch. Neural. 61,561–566 (2004).
   PubMed Web of Science ®Google Scholar
• •Provides an example of delayed start methodology.
   Google Scholar
• Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Eng. J. Med. 321, 1364–1371 (1989).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann. Neural. 40,99–107 (1996).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Hauser RA, Gauger L et aL The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann. Neural. 38,771–777 (1995).
   PubMed Web of Science ®Google Scholar
• Shoulson I. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of parkinsonism. Ann. Neural. 44, S160—S166 (1998).
   Google Scholar
• The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl. J Med. 328, 176–183 (1993).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Anonymous. Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. Arch. Neural. 52,237–245 (1995).
   PubMedGoogle Scholar
• Parkinson Study Group. Does levodopa slow or hasten the progression of Parkinson's disease: the results of the ELLDOPA study. N Eng. J. Med. (2004) (In Press).
   Google Scholar
• •Provides an example of challenges interpreting neuroprotective trials with respect to counfounding by symptomatic effects and biomarker assessment of disease progression.
   Google Scholar
• Seibyl JP, Marek KL, Quinlan D et al. Decreased single-photon emission computed tomographic 11231113-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann. Neurol. 38, 589–598 (1995).
   Google Scholar
• Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with 118F1dopa PET. J. Neurol, Neurosurg. Psychiatry64,314–319 (1998).
   Google Scholar
• Brooks DJ, Frey KA, Marek KL etal. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp. Neurol. 184, S68—S79 (2003).
   Google Scholar
• Marek K. Pramipexole versus levodopa: effects on Parkinson's disease progression assessed by dopamine transporter imaging. Neurology 58, A82—A82 (2002).
   Web of Science ®Google Scholar
• Whone AJ, Remy P, Davis MR et aL The REAL-PET study: slower progression in early Parkinson's disease treated with ropinirole compared withl-dopa. Neurology 58, A82—A82 (2002).
   Web of Science ®Google Scholar
• Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol. 3,309–316 (2004).
   PubMed Web of Science ®Google Scholar
• Sair HI, Doraiswamy PM, Petrella JR. In vivo amyloid imaging in Alzheimer's disease. Neuroradiology 46, 93–104 (2004).
   Google Scholar